Transaction details
Rhea J. Posedel, a member of the board of directors at Aehr Test Systems (NASDAQ:AEHR), sold 7,500 shares of the company’s common stock on April 20, 2026, a transaction disclosed in a Securities and Exchange Commission Form 4 filing submitted the same day. The shares were sold at $88.09 per share, generating proceeds of $660,675. The filing indicates those shares were held indirectly through a trust.
Holdings after the sale
Following the disposition, Posedel’s indirect holdings via the trust are reported at 396,979 shares of common stock. Separately, Posedel directly holds 71,163 shares, a total that includes shares subject to unvested restricted stock units.
Market context
The sale occurred while AEHR shares were trading near their 52-week high of $91.43. At the time of the report, the stock was quoted at $90.15, reflecting a substantial one-year appreciation of 937%.
Company developments
In corporate developments, Aehr Test Systems announced a $41 million production order from a hyperscale customer for package-level burn-in of custom AI processor ASICs. The company described this as the largest order in its history; the package includes high-power test and burn-in systems and deliveries are scheduled to begin in fiscal 2027.
Recent financial results and backlog
For the third quarter of fiscal 2026, Aehr Test Systems reported mixed results. The company posted earnings per share of -$0.05, which beat forecasts, while revenue came in at $10.3 million and was below expectations. Despite the revenue shortfall, Aehr recorded record quarterly bookings of $37.2 million, which the company said pushed its effective backlog to more than $50 million.
Analyst reactions and valuation note
Market participants and analysts have adjusted their outlooks following the bookings momentum and the sizable hyperscale order. Freedom Broker raised its price target to $61, while Lake Street increased its target to $56, both citing demand strength and bookings despite the revenue miss. At the same time, InvestingPro analysis cited in the filing indicates AEHR appears overvalued at current price levels.
What the filing shows
The Form 4 documenting Posedel’s sale was filed on April 20, 2026, and provides a snapshot of insider activity at a company experiencing a combination of significant contract wins, elevated bookings, and mixed near-term financials.
Limitations
If further detail is required about the trust arrangement, the composition of Posedel’s directly held shares, or the specific timing and milestones tied to the fiscal 2027 delivery schedule for the $41 million order, those items are not expanded upon in the Form 4 or the company statements referenced in this report.